BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Dec. 9, 2005
View Archived Issues
Protherics Sends Sepsis Drug To AstraZeneca In $341M Deal
In its most significant deal to date, Protherics plc licensed rights to its late-stage sepsis drug candidate to AstraZeneca plc for a potential £195 million (US$341 million). (BioWorld Today)
Read More
Feeling Lucentis Pressure, QLT Cuts Staff, Restructures
Read More
Synergistic With Velcade, NPI-0052 Heading To Clinic
Read More
Dyax Starts Pivotal Phase III With HAE Treatment DX-88
Read More
GTC Moving ATryn Forward Via Stock Deal Worth $16.7M
Read More
U.S. Patent Disclosures
Read More
Other News To Note
Read More